Alternatives to Dhivy If You Can't Fill Your Prescription

Dhivy is a unique formulation of carbidopa/levodopa — the gold-standard treatment for Parkinson's disease — that can be divided into four precise segments for personalized dosing. But if your pharmacy doesn't carry it or can't order it in time, you and your neurologist may need to consider alternatives.

Important: Never switch Parkinson's medications on your own. Always talk to your neurologist or prescriber before changing your carbidopa/levodopa formulation or dose. Dose conversions are not always 1:1, and changes can significantly impact your symptom control.

First: What Makes Dhivy Different?

Before exploring alternatives, it helps to understand what you'd be giving up. Dhivy's key advantage is its four-segment design: each tablet (25 mg carbidopa/100 mg levodopa) can be snapped into quarter segments of 6.25 mg carbidopa/25 mg levodopa. This allows for dose adjustments in very small increments — useful for patients with motor fluctuations or those early in their disease who need minimal doses.

Option 1: Generic Carbidopa/Levodopa IR Tablets (Closest Alternative)

Generic immediate-release (IR) carbidopa/levodopa tablets contain the exact same active ingredients as Dhivy (carbidopa and levodopa) in the same 25/100 mg strength. They are produced by multiple manufacturers — including Teva, Amneal, and Sun Pharma — and are available at virtually every pharmacy in the U.S.

Key difference: Standard generic tablets do not have Dhivy's precise four-segment scoring. Cutting a standard tablet in half gives you approximately 12.5/50 mg, but cutting to quarter doses is unreliable. If your regimen depends on 6.25/25 mg increments, this is a meaningful limitation to discuss with your neurologist.

Cost: Generic IR tablets are very affordable — as low as $9 per month with a GoodRx coupon — making them the most cost-effective option.

Option 2: Rytary (Carbidopa/Levodopa Extended-Release Capsules)

Rytary is an extended-release formulation of carbidopa/levodopa in capsule form. It uses a multi-bead technology to deliver levodopa over a longer period — roughly 4 to 5 hours — compared to 3 to 4 hours for immediate-release tablets. It's FDA-approved for Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism from carbon monoxide or manganese intoxication.

Key consideration: Rytary doses are NOT interchangeable 1:1 with Dhivy or standard IR tablets. Switching requires a careful dose conversion by your neurologist, typically with a 30% increase in total daily levodopa dose to account for lower bioavailability.

Cost: $800–$1,500 per month without insurance. Typically requires prior authorization. A manufacturer savings card may reduce copay for commercially insured patients.

Option 3: Crexont (Carbidopa/Levodopa ER, FDA-Approved 2024)

Crexont is the newest extended-release carbidopa/levodopa capsule, approved by the FDA in 2024. It uses a patented multi-bead technology that combines immediate-release and sustained-release beads in the same capsule, aiming for smoother levodopa plasma levels throughout the day. Many patients can take it twice daily.

Key consideration: Like Rytary, Crexont is not a direct milligram-for-milligram substitute for Dhivy. Dose conversion must be handled by your neurologist.

Cost: Brand-only; typically $500–$700 per month without insurance. Prior authorization is usually required.

Option 4: Stalevo (Carbidopa/Levodopa/Entacapone)

Stalevo combines carbidopa and levodopa with entacapone, a COMT inhibitor that prevents levodopa from breaking down in the body before it reaches the brain. This extends the duration of each levodopa dose, which can be helpful for patients experiencing "wearing off" between doses.

Key consideration: Stalevo adds a third drug (entacapone) with its own side effects and interactions. It is most appropriate for patients who already have motor fluctuations, not as a general substitute for Dhivy. Generic versions are available.

Option 5: Dopamine Agonists (Different Mechanism)

If carbidopa/levodopa formulations are all unavailable, your neurologist might discuss dopamine agonists as an adjunct or short-term alternative for milder Parkinson's disease. These include:

• Pramipexole (Mirapex): A non-ergoline dopamine agonist available as generic. FDA-approved for both Parkinson's disease and restless legs syndrome.
• Ropinirole (Requip): Another non-ergoline dopamine agonist; generic available. Effective for early PD motor symptoms.
• Rotigotine (Neupro): A dopamine agonist delivered via a once-daily skin patch. Less GI upset than oral agonists.

Dopamine agonists work through a different mechanism than levodopa and are generally less potent for motor symptom control in moderate-to-advanced Parkinson's disease. They are more appropriate for early PD or as add-on therapy. They are not true substitutes for Dhivy in patients who depend on levodopa for adequate symptom control.

Comparison at a Glance

• Generic carbidopa/levodopa IR: Best for: bridge/temporary use. Cost: ~$9/month. Widely available.
• Rytary: Best for: patients benefiting from extended release. Cost: $800–$1,500/month. Requires prior auth.
• Crexont: Best for: patients needing twice-daily ER dosing. Cost: ~$500–$700/month. Brand only.
• Stalevo: Best for: patients with wearing off on levodopa. Adds entacapone.
• Pramipexole/Ropinirole: Best for: early PD or adjunct. Different mechanism; generics available.

Before You Switch: Try to Find Dhivy First

If Dhivy is working well for you, the best option is to keep taking it. Use medfinder to search pharmacies in your area before concluding Dhivy is unavailable. You may find it at a pharmacy you haven't tried. Read our guide on how to find Dhivy in stock near you for step-by-step search strategies.